CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
复制标题
CD36 /CD61 微粒与冠状动脉疾病患者经皮心脏介入治疗的风险以及替格瑞洛的作用相关
DOI：
10.1007/s10557-021-07184-0
复制
发表时间：
2021-04
期刊：
影响因子：
--
通讯作者：
Jingjin Che
中科院分区：
文献类型：
--
作者：
Xue Zhou;Xing Liu;Hongmei Liu;Shuang Dou;Kangyin Chen;Xiaowei Zhang;Weiding Wang;Xuewen Wang;Jingjin Che
目的CD36清道夫受体是动脉粥样硬化和血栓形成的中介物。目的探讨血小板CD36+微粒子(MPS)对冠心病(CAD)患者心血管事件的预测价值及不同抗血小板药物对MPS的影响。方法101例接受阿司匹林治疗的冠心病患者随机分为标准氯吡格雷方案和替卡格雷治疗。分别于术前、术前、术后即刻用流式细胞仪检测总Annexin V-(AV)+MPS、CD61+/AV+MPS、CD36+/CD61+/AV+MPS。结果52例经皮冠状动脉介入治疗(PCI)患者的CD36+/CD61+/AV+MPS水平明显高于49例非经皮冠状动脉介入治疗患者(P<0.05)。基线时CD36+/CD61+/AV+MPS的ROC曲线聚集模型预测冠状动脉介入治疗的风险增加[p=0.009，AUC=0.761(95%CI：0.601至0.922)]。TEG检查显示CD36+/CD61+/AV+MPS比例与R时间、K时间呈显著负相关(r=−0.236，p=00.026；r=−0.288，p=0.006)，与MAADP呈正相关(r=0.226，p=0.045)。冠脉介入治疗组术前血小板抑制率明显高于氯吡格雷组(66.05%±28.76%vs 31.01%±27.33%，p<；0.001)，而术前aV+MPS、CD61+/aV+MPS、CD36+/CD61+/aV+MPS明显低于氯吡格雷(均p<；0.05)。替卡格雷显著降低CD61+/AV+MPS和CD36+/CD61+/AV+MPS的数量，本次试验注册号为ChiCTR1800014908，注册日期为2018.05.01。
PurposeThe CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ microparticles (MPs) released from platelets for cardiovascular event presentation in coronary artery disease (CAD) patients and the effects of different antiplatelet drugs on MPs.MethodsA total of 101 aspirin-treated CAD patients, who were planned to undergo coronary angiography (CAG), were randomized to either a standard clopidogrel regimen or ticagrelor treatment. Total Annexin V-(AV)+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs were quantified by flow cytometry at baseline, before and immediately after the operation. The ADP-induced platelet inhibition rate was measured by thromboelastogram (TEG) examination 1 h before the operation.ResultsThe baseline levels of CD36+/CD61+/AV+ MPs were significantly increased in percutaneous coronary intervention (PCI) patients (n= 52) compared to no-PCI patients (n= 49) (p< 0.05). A ROC-curve clustered model for CD36+/CD61+/AV+ MPs at baseline predicted an increased risk of PCI [p= 0.009, AUC = 0.761 (95%CI: 0.601 to 0.922)]. Moreover, TEG examination showed that the preoperative proportion of CD36+/CD61+/AV+ MPs was significantly negatively correlated with R time and K time (r= − 0.236,p= 00.026;r= − 0.288,p= 0.006), and positively correlated with MAADP(r= 0.226,p= 0.045). Subgroup analysis of PCI group showed that the platelet inhibition rate of ticagrelor was significantly higher (66.05% ± 28.76% vs.31.01% ± 27.33%,p< 0.001), and the number of AV+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs before the operation was significantly lower than clopidogrel (p< 0.05, all).ConclusionThe high levels of CD36+ MPs derived from activated platelets are related to an increased risk of PCI in CAD patients. Ticagrelor significantly reduced the number of CD61+/AV+ MPs and CD36+/CD61+/AV+ MPs.This trial registration number is ChiCTR1800014908 and the date of registration is 2018.05.01.
登录
查看更多内容
影响因子：
3.7
作者：
Chiva-Blanch G;Suades R;Crespo J;Peña E;Padró T;Jiménez-Xarrié E;Martí-Fàbregas J;Badimon L
通讯作者：
Badimon L
影响因子：
3.4
作者：
Williams, Marlene S.;Rogers, Heather L.;Wang, Nae-Yuh;Ziegelstein, Roy C.
通讯作者：
Ziegelstein, Roy C.
影响因子：
6.7
作者：
J. Heemskerk;E. Bevers;T. Lindhout
通讯作者：
J. Heemskerk;E. Bevers;T. Lindhout
影响因子：
4.4
作者：
Tan, KT;Tayebjee, MH;Lip, GYH
通讯作者：
Lip, GYH
影响因子：
20.3
作者：
William A. E. Parker;R. Storey
通讯作者：
William A. E. Parker;R. Storey